Bioshield legislation
This article was originally published in The Gray Sheet
Executive Summary
Sen. Judd Gregg (R- N.H.) plans Senate HELP Committee hearings this fall to consider follow-up legislation to the Project Bioshield Act (S 15) to address, among other topics, corporate liability for products developed under the program. The legislation, approved in the House July 14 following Senate passage May 19, secures $5.6 bil. in funding over the next five years for development of diagnostic and therapeutic countermeasures against bioterrorism agents and ensures rapid regulatory review, when necessary. AdvaMed has backed the Bioshield provisions since the concept was unveiled during President Bush's 2003 State of the Union address. The association also has maintained the importance of liability protection for products used in emergency...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.